NASDAQ · MENS

Jyong Biotech Ltd.

$2.43 +$0.07 (+2.97%) 1D Market open

Key Metrics

$175.19M
Market cap
P/E · TTM
Revenue · TTM
Net income
EPS · TTM
Dividend yield
Free cash flow
Beta · 1Y 1.57
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 18
    From its Apr 13 high, the share price fell 44%.

    Peak close $2.79 on Apr 13; trough close $1.56 on Jun 18. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -44%
  • Feb 23
    The stock moved +35.8% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 23
  • Feb 5
    The stock moved -21.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 5

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$175.19M
Enterprise value
Shares outstanding74.2M
52-wk range$1.43 – $67.00
Avg volume · 20D363.9K
Net cash
Book value / share$-0.34
ExchangeNASDAQ
About Jyong Biotech Ltd.
IPO dateJun 17, 2025
Employees27

Jyong Biotech Ltd is research and develop new drugs for today's great unmet medical needs and planned to manufacture and sell new drugs after receiving regulatory approval.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC — · —

Financial Health

Current ratio0.45
Quick ratio
Debt / equity-0.09
Debt / EBITDA
Net cash
Working capital−$19.27M

Cash Flow · TTM

Operating CF −$3.04M
Capex
Free cash flow
Buybacks $16.37M
Dividends paid
Shareholder yield 9.3%

Piotroski F-Score

Needs two fiscal years of filings

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2025-12-31 · computed by TickerWolf from SEC filings